Dr. Beauregard is an assistant professor in the Department of Radiology and Nuclear Medicine at Laval University, a clinician scientist in the Oncology axis of the CHU Research Centre of Quebec – Laval University, and a specialist in nuclear medicine in the Department of Medical Imaging of the CHU of Quebec. Dr. Jean-Mathieu Beauregard completed his residency in nuclear medicine and his master’s degree in radiobiology at the Université de Sherbrooke. He completed additional training at the Peter MacCallum Cancer Centre in Melbourne, Australia from 2007 to 2010, during which he developed a strong interest in molecular imaging and radionuclide therapy for neuroendocrine tumors. Since his return to the CHU of Quebec, he has set up a new radiopeptide therapy program for neuroendocrine tumors. His research program is multidisciplinary and integrates translational research projects in medical and clinical physics.
Dr. Beauregard’s main clinical research project is the radiopeptide therapy (or PRRT for peptide receptor radionuclide therapy) of patients with neuroendocrine tumors (NETs), where a radioligand (ex. 177Lu-octreotate), binding to the somatostatin receptor expressed by NETs, is administered in several cycles to deliver radiotherapy said internal. We have developed an innovative approach, the personalization of the administered activity, to achieve safe target doses of radiation absorbed by healthy tissue, in order to maximize the irradiation of tumors, without increasing the treatment’s toxicity. Our preliminary results show that we are substantially increasing the radiation dose to tumors compared to the standard regimen where all patients receive the same activity at each cycle.
At the same time, we are working to improve and simplify dosimetry based on SPECT / CT quantitative imaging. To this end, we are fine-tuning the calibration of the SPECT / CT cameras and optimizing the sequence of serial imaging of patient performed after each PRRT treatment cycle in order to achieve the highest precision possible with a minimum of imaging sessions. These serial studies allow us to evaluate the biodistribution of the radiopharmaceutical and its kinetics in different tissues and tumors to derive absorbed radiation doses.
In collaboration with Dr. Girish M. Shah, we are also conducting in vitro and in vivo translational research projects, evaluating novel approaches to PRRT potentiation. One of these is the coadministration of radiosensitizing molecules, such as poly (ADP-ribose) and polymerase (PARP) inhibitors. These inhibit the repair of damages caused to the tumors’ DNA by the PRRT, and thus amplify the therapeutic effects. Another strategy we are studying is to pre-treat NET cells with molecules that can increase their somatostatin receptor expression, thereby promoting increased PRRT radiopharmaceutical accumulation within these cells.
Finally, Dr. Beauregard is also a co-investigator and collaborator on several other clinical research projects using, among other things, positron emission tomography (PET / CT) molecular imaging of prostate cancer and neurodegenerative disorders. Dr. Beauregard supervises graduate students and clinical fellows as part of a complementary training program in nuclear oncology.
- Arguin-Therrien, AmélieMaster studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension firstname.lastname@example.org
6 Rue McMahon
1899-4 / 1899-1
Canada G1R 3S1
- Bélanger, ValérieEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension email@example.com
11, côte du Palais
Canada G1R 2J6
- Bouvet, GuillaumeEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension firstname.lastname@example.org
6, rue McMahon
Canada G1R 2J6
- Desy, AlessandroDoctoral studentHôpital de l'Enfant-Jésus+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
1401, 18e rue
Canada G1J 1Z4
- Forget, VincentMaster studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension firstname.lastname@example.org
6 Rue Mcmahon
Canada G1R 3S1
- Lafrenière, NancyEmployeenancy.email@example.com@crchudequebec.ulaval.ca
- Zamanian, AtefehDoctoral studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension firstname.lastname@example.org
6 Rue McMahon
Canada G1R 3S1
Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CTJournal Article
Clin Nucl Med, 2022.
Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapyJournal Article
EJNMMI Phys, 9 (1), 2022.
Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1Journal Article
J Neurol, 269 (7), 2022.
Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)Journal Article
Eur J Nucl Med Mol Imaging, 49 (2), 2022.
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocolJournal Article
BJU Int, 130 (3), 2022.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerJournal Article
N Engl J Med, 385 (12), 2021.
Optimizing the Schedule of PARP Inhibitors in Combination with Lu-DOTATATE: A Dosimetry RationaleJournal Article
Biomedicines, 9 (11), 2021.
Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systemsJournal Article
EJNMMI Phys, 8 (1), 2021.
Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical TherapiesJournal Article
PET Clin, 16 (4), 2021.
Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case ReportJournal Article
Front Endocrinol (Lausanne), 12 , 2021.
- Chemotherapy-induced upregulation of somatostatin receptors for enhancing therapeutic efficacy of, and eligibility to PRRT of neuroendocrine tumors, from 2020-07-01 to 2022-12-31
- Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2023-12-15
- National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
- Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2023-06-30
- Potentiation of PRRT by chemotherapy-mediated upregulation of somatostatin receptor 2 in NET cell lines-derived tumors in mice and in Lung NET patient-derived tumor explants, from 2022-04-01 to 2024-12-31
- Théranostique personnalisée du cancer de la prostate, from 2022-07-01 to 2024-06-30
- Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31